These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8330062)

  • 1. [Adjuvant chemo-immunotherapy with VBL + INF in renal carcinoma. Long-term results].
    Cocimano V; Marino G; Cevoli R; Marten Perolino R
    Arch Ital Urol Androl; 1993 Apr; 65(2):167-71. PubMed ID: 8330062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interferon and vinblastine in advanced renal carcinoma].
    Vicini D; Franceschetti GP; Mirando P; Ruggieri M; Cardellini P
    Arch Ital Urol Androl; 1993 Apr; 65(2):181-4. PubMed ID: 8330065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
    Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
    J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interferon and vinblastine in presumably operable metastases of renal carcinoma].
    Pizzocaro G; Piva L; Faustini M; Mangiarotti B; Nicolai N; Salvioni R; Milani A; Zanoni F
    Arch Ital Urol Androl; 1993 Apr; 65(2):177-80. PubMed ID: 8330064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant therapy with vinblastine and interferon in metastatic renal carcinoma].
    Cocimano V; Marino G; Brigato R; Cevoli R; Griffa D
    Minerva Urol Nefrol; 1989; 41(3):187-9. PubMed ID: 2617374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience with rIL2 in the treatment of metastatic renal carcinoma].
    Cardellini P; Vicini D; Ruggieri M; Franceschetti GP; Nicrosini S
    Arch Ital Urol Androl; 1993 Apr; 65(2):157-9. PubMed ID: 8330060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma.
    Kriegmair M; Oberneder R; Hofstetter A
    Urology; 1995 May; 45(5):758-62. PubMed ID: 7747370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
    Hernberg M; Muhonen T; Pyrhönen S
    Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant alpha-interferon plus vinblastine in metastatic renal-cell cancer: analysis of response and survival in 58 evaluable patients.
    Bergerat JP; Ford J; Herbrecht R; Dufour P; Oberling F; Jacqmin D; Bollack C; Prevot G; Salze P; Jurascheck F
    Prog Clin Biol Res; 1990; 348():137-50. PubMed ID: 2385604
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
    Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
    Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
    Messing EM; Manola J; Wilding G; Propert K; Fleischmann J; Crawford ED; Pontes JE; Hahn R; Trump D;
    J Clin Oncol; 2003 Apr; 21(7):1214-22. PubMed ID: 12663707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant interferon alpha in renal carcinoma with a high risk of recurrence. Multicenter pilot study].
    Pizzocaro G; Piva L; Faustini M; Nicolai N; Salvioni R; Pisani E; Maggioni A; Mandressi A; Dormia E; Minervini S
    Arch Ital Urol Androl; 1993 Apr; 65(2):173-6. PubMed ID: 8330063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon update.
    Pyrhönen S
    Urologe A; 2004 Sep; 43 Suppl 3():S137-8. PubMed ID: 15148576
    [No Abstract]   [Full Text] [Related]  

  • 15. [Metastasizing kidney cancer. Experience with interferon alfa-2a and vinblastine].
    González Enguita C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Tello Royloa C; Rioja Sanz LA
    Actas Urol Esp; 1990; 14(5):335-8. PubMed ID: 2288249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal cell carcinoma-interferon therapy, its clinical adaptation and limitations].
    Noguchi S; Hosaka M
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2383-9. PubMed ID: 1952957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of treatment with interferon and vinblastine in renal cancer].
    Ojea Calvo A; Castro Iglesias AM; Rodríguez Iglesias B; Benavente J; Barros JM; Figueiredo L; Eceolaza J; Nogueira March JL
    Actas Urol Esp; 1992 Jun; 16(6):507-11. PubMed ID: 1509922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma.
    Rizzo M; Bartoletti R; Selli C; Sicignano A; Criscuolo D
    Eur Urol; 1989; 16(4):271-7. PubMed ID: 2670581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical study on renal cell carcinoma].
    Yanagawa M; Suzuki S; Kameda K; Nakano S; Kinbara H; Araki T; Sakurai M; Hioki T; Sugimura Y; Tochigi H
    Hinyokika Kiyo; 1991 Oct; 37(10):1215-21. PubMed ID: 1755414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.